TABLE 2.
Mean tedizolid pharmacokinetic parameters of the hepatic-impairment groupa
| Study group | Cmax (μg/ml) | Tmax (h) | AUC0–t (μg · h/ml) | AUC0–∞ (μg · h/ml) | t1/2 (h) |
|---|---|---|---|---|---|
| Moderate impairment (n = 8) | 2.08 (0.74) | 1.75 (0.50–3.00) | 29.89 (16.76) | 30.47 (17.50) | 14.94 (3.49) |
| Matched controls (n = 8) | 1.85 (0.49) | 2.00 (1.00–4.00) | 22.80 (5.63) | 23.00 (5.70) | 13.42 (3.93) |
| Severe impairment (n = 8) | 2.20 (1.07) | 2.00 (0.50–3.00) | 34.80 (20.72) | 35.23 (21.13) | 14.19 (2.92) |
| Matched controls (n = 8) | 2.12 (0.80) | 3.00 (1.00–8.00) | 24.37 (8.03) | 24.56 (8.05) | 13.68 (3.71) |
a
AUC0–t, integrated area under the curve based on samples from time zero to the time of the last collected sample; AUC0–∞, area under the curve based on the terminal rate constant; Cmax, maximum concentration observed with a 200-mg dose; t1/2, tedizolid half-life; Tmax, time to reach the maximum concentration. Pharmacokinetic parameters are presented as means (standard deviations), except for Tmax values, which are presented as medians (ranges).